VALNEVA SE ADR
NASDAQ: VALN (Valneva SE)
Kemas kini terakhir: 1 jam lalu6.43
-0.15 (-2.28%)
| Penutupan Terdahulu | 6.58 |
| Jumlah Dagangan | 22,286 |
| Harga / Jualan (P/S) | 3.51 |
| Harga / Buku (P/B) | 6.58 |
| Julat 52 Minggu |
| Margin Keuntungan | -43.21% |
| Margin Operasi (TTM) | -12.11% |
| EPS Cair (TTM) | -1.31 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 50.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 120.48% |
| Nisbah Semasa (MRQ) | 2.70 |
| Aliran Tunai Operasi (OCF TTM) | -46.93 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -122.62 M |
| Pulangan Atas Aset (ROA TTM) | -19.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -44.11% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Valneva SE | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Institusi | 0.82% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| General American Investors Co Inc | 30 Jun 2026 | 354,361 |
| Vsm Wealth Advisory, Llc | 30 Jun 2026 | 10,000 |
| Steigerwald, Gordon & Koch Inc. | 30 Jun 2026 | 1,250 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |